HCPCS code J9035: Bevacizumab, per 10 mg2026 Medicare rate & RVUs

Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.

What J9035 covers

J9035 identifies bevacizumab, the reference product sold as Avastin, used in cancer treatment. It is typically administered by intravenous infusion in regimens for cancers including metastatic colorectal, non-small cell lung, renal cell, cervical, ovarian, fallopian tube, and peritoneal cancers, as well as glioblastoma. Hospital outpatient departments and physician-office infusion clinics commonly report the drug when they furnish this product. The code represents the medication, not the infusion service.

CMS assigns status E, excluding J9035 from the physician fee schedule. When Medicare covers the drug, payment is under another payment method; the HCPCS pricing method identifies it as a Part B drug generally paid using CMS quarterly ASP drug pricing files. Coverage is left to the Medicare contractor’s judgment. One unit represents 10 mg, so a 100 mg administered dose corresponds to 10 units. Report the infusion administration separately when performed and separately reportable.

This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.

Where J9035 pays more and less

The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.

109 of 109 payment localities

J9035 rates by state

Office rate range in each state. Select a state to see its payment localities.

How the J9035 rate is calculated

Each of J9035’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.

Payment rules and modifiers for J9035

J9035 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.

J9035 compared with similar codes

How to choose

Q5107Mvasi injectionPer 10 mg

Use Q5107 when the administered product is bevacizumab-awwb; J9035 identifies the reference bevacizumab product.

Q5118Zirabev injectionPer 10 mg

Use Q5118 for bevacizumab-bvzr. Select between it and J9035 based on the product administered.

Q5126Alymsys injectionPer 10 mg

Q5126 identifies bevacizumab-maly, while J9035 identifies the reference product.

Codes related to J9035

Related codes aren’t interchangeable: bill the code that matches the service performed.

Where these rates come from

FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.

CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027

Open CMS sourceHow we calculate rates